Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_assertion type Assertion NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_head.
- NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_assertion description "[Our study demonstrated that SLE patients carrying the genotypes with GSTP1 codon 105 mutation [GSTP1*-105I/V (heterozygote) and GSTP1*-105 V/V (homozygote)] had an increased risk of myelotoxicity when treated with pulsed high-dose CTX therapy (Odds ratio (OR) 5.00, 95% confidence interval (CI) 1.96, 12.76); especially in patients younger than 30 years (OR 7.50, 95% CI 2.14, 26.24), or in patients treated with a total CTX dose greater than 1.0 g (OR 12.88, 95% CI 3.16, 52.57).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_provenance.
- NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_assertion evidence source_evidence_literature NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_provenance.
- NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_assertion SIO_000772 16995867 NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_provenance.
- NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_assertion wasDerivedFrom befree-2016 NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_provenance.
- NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_assertion wasGeneratedBy ECO_0000203 NP570652.RA99Kd7EqsNj4le1fnl6bgT1eCwDsyl9m5G5uMjZfzlZ4130_provenance.